soul trial oral semaglutide cardiovascular outcomes results 2025 2024 nejm 💥Soul study group recently shared Cardiovascular outcomes of semaglutide and

Mitochondrial protective and anti-apoptotic effects of Rhodiola crenulata extract on hippocampal neurons in a rat model of Alzheimer's disease

Real-world outcomes: According to a 72-week phase 3b trial, adults with obesity (but without diabetes) treated with tirzepatide were significantly more likely to lose at least 10% or 15% of their body weight than those treated with semaglutide

Numerous studies have reported that patients with mood and anxiety-related disorders are characterized by increased circulating inflammatory cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), their soluble receptors, and acute phase reactants such as C-reactive protein (CRP) (Sluzewska, 1999

Supports the phases of detoxification and toxin removal from the body

Semaglutide and tirzepatide have demonstrated weight reductions of 10 to 20 percent in many patients